Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study by Renaud Felten, Nan Shen, Julia Weinmann-Menke, Ana Malvar, Peter Gergely, Tamas Shisha, Carole Sips, André Serra-Roma, Markus Weiss, Rambabu Danekula, Jan Rohr

Get full text

Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort by Rangi Kandane-Rathnayake, Worawit Louthrenoo, CS Lau, Laniyati Hamijoyo, Jiacai Cho, Aisha Lateef, Shue Fen Luo, Yeong-Jian Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Yi-Hsing Chen, Shereen Oon, Madelynn Chan, Sargunan Sockalingam, Yanjie Hao, Zhuoli Zhang, Sang-Cheol Bae, Jun Kikuchi, Tsutomu Takeuchi, Yasuhiro Katsumata, BMDB Basnayake, Fiona Goldblatt, Sean O’Neill, Kristine Pek Ling Ng, Nicola Tugnet, Mark Sapsford, Yih Jia Poh, Cherica Tee, Michael Tee, Naoaki Ohkubo, Adrienne O’Donnell Lefeber, Tamas Shisha, Yoshiya Tanaka, Vera Golder, Mandana Nikpour, Alberta Hoi, Peter Gergely, Eric Morand

Get full text